Dr. Pu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
155 South Huntington Avenue
Boston, MA 02130Phone+1 917-822-5065
Summary
- Dr. Jeffrey Pu is an Oncologist based in Syracuse, NY, with a specific focus in Hematologic Oncology. He completed his medical training at notable institutions such as Johns Hopkins University and the Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital, having high expertise in multiple areas including amyloidosis, aplastic anemia, myelodysplasia and myelofibrosis. His most recent employment has been as an Attending Physician at Upstate University Hospital since 2017. Dr. Pu has several significant publications in the field of Hematology & Oncology and he is actively involved in clinical trials like ‘Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma’ and ‘Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)’.
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2008 - 2011
- New York Blood CenterFellowship, Blood Banking/Transfusion Medicine, 2006 - 2007
- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2004 - 2006
- Shanghai Jiao Tong University School of MedicineClass of 1987
Certifications & Licensure
- MA State Medical License 2023 - 2026
- LA State Medical License 2024 - 2025
- NY State Medical License 2006 - 2025
- SC State Medical License 2020 - 2025
- AZ State Medical License 2020 - 2024
- PA State Medical License 2012 - 2024
- MD State Medical License 2008 - 2013
- American Board of Internal Medicine Hematology
Clinical Trials
- Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) Start of enrollment: 2012 May 01
- Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma Start of enrollment: 2012 Nov 19
Publications & Presentations
PubMed
- Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation.Karen Ballen, Tao Wang, Naya He, Jennifer M Knight, Sanghee Hong
Transplantation and Cellular Therapy. 2024-10-01 - 1 citationsNovel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference.Andrew Wang, James Liu, Jeffrey J Pu
Journal of Hematology & Oncology. 2023-05-12 - The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation.Hao Wang, Kristin N Berger, Elizabeth L Miller, Wei Fu, Larisa Broglie
Therapeutic Advances in Hematology. 2023-01-01
Press Mentions
- Remembering Thomas Brock, Xavier Becerra Confirmed as U.S. Health Secretary, and MoreJune 1st, 2021
Professional Memberships
- Member
- Member
- American Society for Blood and Marrow TransplantationMember
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: